Bringing the next evolution of medicine to market
Osiris Therapeutics, Inc. is committed to developing its proprietary adult stem cell technology in order to provide physicians with next-generation tools for the treatment and functional restoration of damaged or diseased tissues. The multi-potential character of our stem cell product candidates provides the basis for a cell therapy platform that represents a virtually limitless number of indications.
 |
|
Prochymal is being evaluated in Phase III clinical trials for three indications, including steroid refractory acute graft versus host disease (GvHD), newly diagnosed acute GvHD and also Crohn's disease, and is the only stem cell therapeutic currently designated by the FDA as both an Orphan Drug and Fast Track product. |
|
Prochymal is also being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type 1 diabetes, and the repair of lung tissue in patients with pulmonary disease. |
|
Osiris has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. |
|
 |
|
Chondrogen is currently being evaluated in clinical trials for the treatment of osteoarthritis in the knee. Enrollment for this trial has been completed. |
|
|
Product Pipeline Osiris is continuing to research possible applications of its technology for use in new indications. |
